From the Journals

In head and neck cancer, better outcomes seen in patients with overweight


 

FROM JAMA NETWORK OPEN

Importance of nutritional support during treatment highlighted

In an interview, Ari Rosenberg, MD, of the University of Chicago Medicine, commented that the findings highlighted the importance of expert nutritional supportive care during treatment and monitoring for patients with advanced head and neck cancers undergoing chemoradiation.

“Nutritional status is very important both at baseline and during treatment,” Dr. Rosenberg said. “Even small changes in weight or BMI can be a key indicator of supportive care during chemoradiation and represent a biomarker to guide supportive management. ... The take home message is that patients should be treated at centers that have a high volume of advanced head and neck cancer patients, which have all the supportive components and expertise to optimize treatment delivery and maximize survival.”

Dr. Ma and colleagues’ study was funded by the National Cancer Institute Cancer Center. None of its authors declared financial conflicts of interest. Dr. Rosenberg disclosed receiving consulting fees from EMD Serono related to head and neck cancer treatment.

Pages

Recommended Reading

2023 Rare Diseases Report: Cancers
MDedge Hematology and Oncology
NORD: Making Progress Through Collaboration
MDedge Hematology and Oncology
The Complex Challenge of Survival After HPV-Associated Oropharyngeal Cancer
MDedge Hematology and Oncology
Widespread carboplatin, cisplatin shortages: NCCN survey
MDedge Hematology and Oncology
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
MDedge Hematology and Oncology
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
MDedge Hematology and Oncology
DEI training gives oncology fellows more confidence
MDedge Hematology and Oncology
Huge underuse of germline testing for cancer patients
MDedge Hematology and Oncology
CBSM phone app eases anxiety, depression in cancer patients
MDedge Hematology and Oncology
Multiprong strategy makes clinical trials less White
MDedge Hematology and Oncology